Skip to content
Resources > Reports

How Artificial Intelligence is Reshaping Drug Development

Interest in artificial intelligence (AI) solutions for new medication development is exploding and fueled by pressures to reduce the time and cost it takes to bring new drugs to market. Also stoking the trend are advances in AI technology and computer processing speed, in addition to the abundance of available data that feed AI models.

In this report, we explore developments and debates in AI-based drug development with first-person insights from the AlphaSense expert transcript library, your single-source solution for quality expert perspectives.

Download our report now to learn what industry experts say about how AI is reshaping the drug development landscape.

Explore more

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.